ArticleHematological oncology2022

Dissecting the impact of bromodomain inhibitors on the Interferon Regulatory Factor 4-MYC oncogenic axis in multiple myeloma.

Alessandro Agnarelli et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.